The global cancer monoclonal antibodies market size was valued at USD 48.30 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 65.5 Billion by 2033, exhibiting a growth rate (CAGR) of 3.4% during 2025-2033. North America currently dominates the market, holding a significant market share of 38.7% in 2024, attributed to its advanced healthcare infrastructure, early...